NCT00532727Unknown3 期
Triple Negative Trial: A Randomised Phase III Trial of Carboplatin Compared to Docetaxel for Patients With Metastatic or Recurrent Locally Advanced ER-, PR- and HER2- Breast Cancer.
Institute of Cancer Research, United Kingdom1 个研究点 分布在 1 个国家目标入组 400 人开始时间: 2008年1月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 发起方
- 入组人数
- 400
- 试验地点
- 1
- 主要终点
- Response: Response will be evaluated after three and six cycles of chemotherapy using modified Response Evaluation Criteria in Solid Tumours (RECIST) criteria, with appropriate clinical assessment and radiological investigations.
研究概览
简要总结
The purpose of this study is to determine whether there is greater activity for carboplatin than a taxane standard of care (docetaxel) in women with ER-, PR- and HER2- breast cancer. The trial aims to recruit between 370 and 450 patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed ER-, PR-, primary breast cancer
- •Histologically confirmed HER2- primary breast cancer
- •Measurable confirmed metastatic or recurrent locally advanced disease unsuitable for local therapy but suitable for taxane chemotherapy
- •Patients with stable, treated bain metastases will be eligible providing informed consent can be given and that other sites of measurable disease are present.
- •Patients with bone metastases currently receiving bisphosphonates for palliation will be eligible providing informed consent can be given and that other sites of measurable disease are present
- •ECOG Performance Status 0, 1, or 2
- •Adequate haematology, biochemical indices (FBC, U & Es)
- •LFTs = Normal bilirubin, AST and/or ALT = 3 x ULN if Alk Phos >5 x ULN (or an isolated elevation AST/ALT of ≤5 x ULN
- •Adequate renal function - Creatinine clearance of >25mls per minute
- •Written informed consent, able to comply with treatment and follow up
排除标准
- •Original primary tumour or subsequent relapse known to be positive for any of ER, PR, or HER2 receptors
- •Patients unfit for chemotherapy or those with neuropathy >grade 1 (sensory or motor)
- •Known allergy to platinum compounds or to mannitol
- •Known sensitivity to taxanes
- •Patients with inoperable locally advanced disease suitable for local radiotherapy or an anthracycline containing regimen
- •Previous chemotherapy for metastatic disease other than an anthracycline as in inclusion criteria above
- •Previous exposure to a taxane in adjuvant chemotherapy within 12 months of trial entry
- •Previous treatment with a taxane for recurrent locally advanced disease
- •Previous treatment with a platinum chemotherapy drug
- •LFTs = Abnormal bilirubin (> ULN), AST and/or ALT >3 X ULN and Alk Phos >5 x ULN (or an isolated elevation AST/ALT of >5 x ULN)
- •Patients with a life expectancy of less than 3 months
- •Previous malignancies other than adequately treated in situ carcinoma of the uterine cervix or basal or squamous call carcinoma of the skin, unless there has been a disease free interval of at least 10 years
- •Previous or synchronous second breast cancer (unless also confirmed ER-, PR- and HER2-)
- •Patients with bone limited disease
- •Other serious uncontrolled medical conditions or concurrent medical illness likely to compromise life expectancy and/or the completion of trial therapy
- •Pregnant, lactating or potentially childbearing women not using adequate contraception
研究组 & 干预措施
Arm A
Experimental
Carboplatin
干预措施: Carboplatin (Drug)
Arm B
Active Comparator
Docetaxel
干预措施: Docetaxel (Drug)
结局指标
主要结局
Response: Response will be evaluated after three and six cycles of chemotherapy using modified Response Evaluation Criteria in Solid Tumours (RECIST) criteria, with appropriate clinical assessment and radiological investigations.
时间窗: Time from start of treatment to 18 weeks
次要结局
- Time to progression: this will be defined according to RECIST criteria and will be measured from the start of treatment until the confirmation of progression(Time from start of treatment until confirmation of progression)
- Progression free survival: this will be defined according to RECIST criteria and will be measured from the start of treatment until the confirmation of progression or death.(Time from start of treatment until confirmation of progression or death)
- Overall survival: this will be defined as time from randomisation until death from any cause in the intention to treat population(Time from randomisation until death from any cause)
- Toxicity will be assessed throughout the treatment period using the National Cancer Institute Common Terminology Criteria for Adverse Events version three (NCI CTCAE v3.0)(Time from start of treatment to 18 weeks)
- Time to treatment failure: this will be defined as time from randomisation to discontinuation of protocol treatment for any reason, or progression of disease as defined by RECIST(Time from randomisation to discontinuation of protocol treatment for any reason, or progression of disease)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
A Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults With Previously Untreated Low Grade GliomaLow Grade GliomaNCT02455245Alicia Lenzen95
进行中（未招募）
3 期
Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant ChemotherapyEstrogen Receptor NegativeHER2/Neu NegativeInvasive Breast CarcinomaProgesterone Receptor NegativeStage II Breast CancerStage IIA Breast CancerStage IIB Breast CancerStage III Breast CancerStage IIIA Breast CancerStage IIIB Breast CancerStage IIIC Breast CancerTriple-Negative Breast CarcinomaNCT02445391ECOG-ACRIN Cancer Research Group415
已完成
3 期
Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)Fallopian Tube CancerPeritoneal NeoplasmsOvarian CancerNCT03740165Merck Sharp & Dohme LLC1,367
招募中
3 期
Phase 3 Trial of Carboplatin in Triple Negative Breast Cancer Patient with Residual Invasive Carcinoma After Neoadjuvant ChemotherapyJPRN-jRCTs051180210Kunihisa Tomonari162
已完成
3 期
Phase 3 Trial of Carboplatin in Triple Negative Breast Cancer Patient with Residual Invasive Carcinoma After Neoadjuvant Chemotherapy(Transitioned to jRCT)JPRN-UMIN000030780Kobe University270